ATEZOLIZUMAB

Description

Atezolizumab (Tecentriq®) – Immunotherapy for Cancer Treatment

Atezolizumab, marketed under the brand name Tecentriq®, is a prescription immunotherapy drug used in the treatment of several cancers, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), urothelial carcinoma, and small cell lung cancer (SCLC). Belonging to the class of PD-L1 inhibitors, Atezolizumab works by blocking the PD-L1 protein, which helps cancer cells evade detection by the immune system. This allows the body’s immune cells to recognize and attack cancer more effectively.

At Oncomed Pharmacy, we supply genuine Atezolizumab/Tecentriq injections from trusted manufacturers, ensuring safe and effective delivery of oncology medicines countrywide.

________________________________________

Key Features of Atezolizumab (Tecentriq®)

• Indications:

o Non-small cell lung cancer (NSCLC)

o Small cell lung cancer (SCLC)

o Triple-negative breast cancer (TNBC)

o Hepatocellular carcinoma (HCC)

o Urothelial carcinoma (bladder cancer)

• Formulation: Injectable solution for intravenous infusion.
• Mechanism of Action: PD-L1 immune checkpoint inhibitor that boosts the body’s natural defense against cancer.
• Patient Benefit: Improves survival outcomes and provides an advanced option beyond traditional chemotherapy.

________________________________________

Why Choose Tecentriq from Oncomed Pharmacy?

• 100% authentic and quality-assured oncology medications.
• Competitive pricing with countrywide shipping.
• Professional handling, secure packaging, and cold-chain logistics where required.
• Trusted supplier specializing in cancer immunotherapy drugs.

________________________________________

Uses of Atezolizumab (Tecentriq®)

• First-line and subsequent-line treatment for lung cancer (NSCLC and SCLC).
• Treatment for metastatic triple-negative breast cancer in combination therapy.
• Management of advanced bladder cancer (urothelial carcinoma).
• Therapy for liver cancer (HCC) when other treatments are not suitable.